Retrospective analysis of the effectiveness and tolerability of nab ‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

ConclusionsNab ‐paclitaxel has a good clinical response profile in Chinese elderly patients with stage IIIB–IV NSCLC. Prospective clinical trials are needed to confirm these results.Key pointsSignificant findings of the studyNanoparticle albumin ‐bound paclitaxel (nab‐paclitaxel) has a good clinical response profile in Chinese elderly (≥65 years) patients with stage IIIB‐IV non‐small‐cell lung cancer (NSCLC), with acceptable and manageable adverse events.What this study addsPreliminary evidence shows a good clinical response from treatment with nab ‐paclitaxel in Chinese elderly patients with advanced NSCLC.

Source: Thoracic Cancer - March 16, 2020 Category: Cancer & Oncology Authors: Shuhang Wang, Qiuping Liang, Yujia Chi, Minglei Zhuo, Tongtong An, Jianchun Duan, Zhijie Wang, Yuyan Wang, Jia Zhong, Xue Yang, Hanxiao Chen, Jie Wang, Jun Zhao Tags: ORIGINAL ARTICLE Source Type: research